Up to 10% of people prescribed statins to lower their LDL cholesterol develop painful muscle aches severe enough to stop taking the drugs, and a preliminary 2025 mouse study published in the Journal of Clinical Investigation suggests the culprit may be a genetic mutation in the person — not the drug itself — that triggers a flood of calcium into muscle cells.
Statins remain among the most effective and proven therapies for lowering “bad” cholesterol and cutting cardiovascular risk, but statin-associated muscle symptoms, or SAMS, are the single most common reason patients discontinue them.
Why a Gene Mutation — Not the Statin Alone — May Trigger the Pain
Researchers divided mice into two groups: genetically unmodified “wild-type” mice and mice carrying a mutation affecting skeletal muscle receptors. Both groups received simvastatin, and the mutated group proved far more prone to SAMS. The mutation alters calcium release when the statin enters the system, causing an influx of calcium into muscle cells — and the pain that follows.
Genetic Research Explains Statin Muscle Effects
- Muscle pain on statins is common — roughly 1 in 10 people — and it is a leading reason patients quit the drug.
- Early mouse research points to a genetic mutation that changes how muscle cells handle calcium, not the statin itself, as a possible trigger.
- Never stop a statin on your own; doctors can switch the statin type, lower the dose, or move to alternatives such as PCSK9 inhibitors or bempedoic acid.
What Cardiologists Say the Mouse Model Means for Human Patients
When a mechanism is backed by basic science and clinical research, it becomes easier to counsel patients, Dr. Benziger explains.
The study has limits worth stating plainly: it was conducted in a mouse model, and future research must determine whether the findings translate to humans. “These findings have only been studied in a mouse model,” Dr. Chen notes. “Future research will be needed to determine whether the findings translate to humans as well.”
Managing SAMS Today: Dose Holidays, Switches, and Alternatives
If symptoms return, she advises working with a physician to switch to a different statin or decrease the dose. In many cases, side effects resolve once switching strains, Dr. Chen says. For those who cannot tolerate statins at all, Dr. Benziger warns against giving up on cholesterol management: “The key is getting the LDL to goal!”
| Approach for SAMS | What it involves | Source perspective |
|---|---|---|
| Switch statin or lower dose | Change molecule or reduce dosage if symptoms return | Advised by Dr. Benziger; Dr. Chen notes many resolve after switching |
| Non-statin alternatives | PCSK9 inhibitors or bempedoic acid for intolerant patients | Suggested by Drs. Chen and Benziger for high-risk patients |
High-Risk Groups Must Monitor LDL Treatment
Do not stop a prescribed statin without medical supervision. Patients with diabetes mellitus, chronic kidney disease, prior heart disease, or an elevated coronary artery calcium score should be especially vigilant about maintaining LDL control through some therapy, whether statin or alternative.
The Road Ahead: From Mouse Mechanism to Human Therapy
References
- Journal of Clinical Investigation — preliminary 2025 mouse study on genetic mutation and statin-associated muscle symptoms
- American College of Cardiology, Prevention of Cardiovascular Diseases Council — Dr. Catherine Benziger, M.D.
- MemorialCare Saddleback Medical Center, Structural Heart Program — Dr. Cheng-Han Chen, M.D.
- Prevention — original reporting on SAMS prevalence and the 2025 study
